Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunological Memory01:23

Immunological Memory

616
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
616
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

243
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
243

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variability in Cardiac Stress Test Interpretation: Agreement Between Enrollment Sites and Core Laboratories in the Global ISCHEMIA Trial.

Circulation. Population health and outcomes·2026
Same author

Cryptococcal Meningitis: Comparison of Short- (≤ 1 Week) Versus Longer-duration (> 1 Week) Liposomal Amphotericin B Induction Therapy and Factors Associated With Clinical Outcomes in HIV and Non-HIV Patients.

Open forum infectious diseases·2026
Same author

Questions Regarding the ISCHEMIA-PREDICT Mortality Risk Score.

European journal of preventive cardiology·2026
Same author

Residual Angina Following Complete Revascularization in the ISCHEMIA Trial: Frequency, Clinical Characteristics, Health Status, and Cardiovascular Outcomes.

Journal of the American Heart Association·2026
Same author

The role of microRNAs in cardiovascular disease associated with the consumption of ultra-processed foods: a comprehensive review.

Frontiers in nutrition·2026
Same author

Telework and Employee Well-Being During the COVID-19 Pandemic: A Two-Wave Survey of Employees at a Texas Health Sciences University.

Archivos de prevencion de riesgos laborales·2026

Related Experiment Video

Updated: Jul 5, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

761

COVID-19 Convalescent Plasma Therapy: Long-term Implications.

Hyunah Yoon1, Yi Li2, Keith S Goldfeld2

  • 1Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.

Open Forum Infectious Diseases
|January 25, 2024
PubMed
Summary

COVID-19 convalescent plasma (CCP) did not improve long-term post-acute sequelae (PASC) symptoms. Demographic factors like sex, age, and infection timing significantly influenced PASC symptom reporting 18 months after hospitalization.

Keywords:
COVID-19 convalescent plasmaPASCPatient-Reported Outcomes Measurement Information Systemacute hypoxic COVID-19long COVID

More Related Videos

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
05:30

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies

Published on: January 31, 2025

415
Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

15.8K

Related Experiment Videos

Last Updated: Jul 5, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

761
Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
05:30

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies

Published on: January 31, 2025

415
Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

15.8K

Area of Science:

  • Infectious Diseases
  • Immunology
  • Public Health

Background:

  • The long-term effects of COVID-19 treatments on Post-Acute Sequelae of SARS-CoV-2 infection (PASC) remain largely unknown.
  • Investigating the impact of COVID-19 convalescent plasma (CCP) on PASC symptoms and general health is crucial for understanding long-term recovery.

Purpose of the Study:

  • To evaluate the 18-month efficacy of COVID-19 convalescent plasma (CCP) therapy in mitigating Post-Acute Sequelae of SARS-CoV-2 infection (PASC) symptoms.
  • To assess the long-term impact of CCP on general health and Patient-Reported Outcomes Measurement Information System (PROMIS) scores in hospitalized COVID-19 patients.

Main Methods:

  • The CONTAIN-Extend study followed 281 participants from the CONTAIN COVID-19 trial for 18 months post-hospitalization.
  • Data collection included symptom surveys, global health assessments, and biospecimen analysis.
  • Multivariable regression analyses were used to assess associations between CCP treatment arms and PASC symptoms, adjusting for relevant covariates.

Main Results:

  • No significant differences in PASC symptoms or PROMIS scores were observed between the CCP and placebo groups.
  • Female sex, age between 45-64 years, and enrollment during April-June 2020 were associated with increased general symptoms and poorer physical health.
  • Hispanic and Black participants reported poorer physical health outcomes compared to White participants.

Conclusions:

  • COVID-19 convalescent plasma (CCP) therapy showed no lasting benefit for Post-Acute Sequelae of SARS-CoV-2 infection (PASC) symptoms or overall health at 18 months.
  • Demographic factors including sex, age, and the timing of acute infection are significant predictors of long-term symptom reporting and health outcomes after COVID-19 hospitalization.